Overview

• Endocrinologic medication developer's Q4 revenue missed analysts' expectations

• Company's Q4 net income declined 21% from last year

• Operational disruptions during pharmacy transition impacted ability to meet demand

Outlook

• Corcept projects full-year 2026 revenue between $900 mln and $1,000 mln

• Company expects long-term expansion of Cushing’s syndrome business

• Corcept anticipates FDA approval for relacorilant in Cushing’s syndrome

Result Drivers

• DEMAND SURGE - Increased physician recognition of Cushing's syndrome prevalence drove demand for treatments

• CAPACITY CONSTRAINTS - Previous specialty pharmacy vendor's capacity constraints limited ability to meet demand

• PHARMACY TRANSITION - Operational disruptions during transition to new specialty pharmacy impacted ability to meet demand

Company press release: ID:nBwprpYxa

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Revenue	Miss	$202.13 mln	$254.94 mln (5 Analysts)
Q4 EPS		$0.20
Q4 Net Income		$24.29 mln

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Corcept Therapeutics Inc is $100.00, about 183% above its February 23 closing price of $35.34

• The stock recently traded at 64 times the next 12-month earnings vs. a P/E of 41 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.